This story was corrected on January 17 to more accurately reflect Packard BioScience’s microarray strategy. The company has cancelled plans to sell DNA chips, not microarrays, as previously reported.

SAN FRANCISCO, Jan 8 – Packard BioScience has cancelled plans to commercialize DNA chips after determining that Affymetrix’ domination in the market was too formidable, a company spokesman said Monday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.